← Back to Screener
Greenwich LifeSciences, Inc. (GLSI)
Price$28.51
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)204.84%
Price vs S&P 500 (4W)5.47%
VGM Score62.42
Market Capitalization$362.64M
All Metrics
Book Value / Share (Quarterly)$0.16
P/TBV (Annual)58.29x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)13.65%
EPS (TTM)$-1.46
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-1.46
EPS (Annual)$-1.21
ROI (Annual)-623.07%
Cash / Share (Quarterly)$0.28
ROA (Last FY)-385.68%
EBITD / Share (TTM)$-1.47
ROE (5Y Avg)-167.76%
Cash Flow / Share (Annual)$-0.55
P/B Ratio165.97x
P/B Ratio (Quarterly)62.07x
Net Income / Employee (Annual)$-3,947,200
ROA (TTM)-565.47%
EPS Incl Extra (Annual)$-1.21
Current Ratio (Annual)2.62x
Quick Ratio (Quarterly)2.35x
3-Month Avg Trading Volume0.24M
52-Week Price Return163.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.16
52-Week High$34.10
EPS Excl Extra (Annual)$-1.21
26-Week Price Return220.77%
Quick Ratio (Annual)2.62x
13-Week Price Return-6.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.35x
Enterprise Value$358.84M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.31
3-Month Return Std Dev86.49%
Net Income / Employee (TTM)$-4,868,900
ROE (Last FY)-623.07%
EPS Basic Excl Extra (Annual)$-1.21
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.46
ROI (TTM)-1042.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.19
Price vs S&P 500 (52W)135.65%
Year-to-Date Return24.58%
5-Day Price Return-5.33%
EPS Normalized (Annual)$-1.21
ROA (5Y Avg)-118.83%
Month-to-Date Return10.82%
Cash Flow / Share (TTM)$-0.48
EBITD / Share (Annual)$-1.23
ROI (5Y Avg)-167.75%
EPS Basic Excl Extra (TTM)$-1.46
P/TBV (Quarterly)62.07x
P/B Ratio (Annual)58.25x
Book Value / Share (Annual)$0.19
Price vs S&P 500 (13W)-16.66%
Beta1.37x
Revenue / Share (TTM)$0.00
ROE (TTM)-1042.76%
52-Week Low$7.78
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLSIGreenwich LifeSciences, Inc. | — | — | B | $28.51 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in patients with HER2/neu-expressing tumors, which represent approximately 75% of breast cancers. The company is advancing GLSI-100 through its Phase III Flamingo-01 trial and expanding operations into Europe with plans to establish up to 150 clinical trial sites globally.